Serelaxin Inhibits Lipopolysaccharide-induced Inflammatory Response in Cardiac Fibroblasts by Activating Peroxisome Proliferator-activated Receptor-γ and Suppressing the Nuclear Factor-Kappa B Signaling Pathway

Serelaxin (sRLX) has an inhibitory effect on fibrosis. However, whether the antifibrotic effects of sRLX are achieved by inhibiting the inflammatory response has not been clarified. This study aimed to investigate the role of sRLX in lipopolysaccharide (LPS)-induced inflammation in cardiac fibroblas...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xueping, Lv, Yehui, Li, Zhihong, Yang, Zhifang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Journal of Cardiovascular Pharmacology 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473033/
https://www.ncbi.nlm.nih.gov/pubmed/37418294
http://dx.doi.org/10.1097/FJC.0000000000001447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473033/
https://www.ncbi.nlm.nih.gov/pubmed/37418294
http://dx.doi.org/10.1097/FJC.0000000000001447

Ejemplares similares